FDA drug center head Tracy Beth Hoeg expected to leave today, according to source reports

The anticipated departure of Tracy Beth Hoeg from the FDA could signal potential shifts in regulatory approaches or priorities within the agency.

Newsquawk StaffPublished On the live feed at , 20 minutes before this page
Newsquawk headlinesUTC

US State Department official to Al Jazeera says the atmosphere of the second day of Lebanon and Israel talks is extremely positive and exceeded expectations

Labour NEC has given Andy Burnham to stand in Makerfield by-election.

FDA drug center head Tracy Beth Hoeg expected to leave today, according to source reports

European Closes: Euro Stoxx 50 -1.74% at 5,824, Dax 40 -2.05% at 23,955, FTSE 100 -1.71% at 10,195, CAC 40 -1.60% at 7,953, FTSE MIB -1.87% at 49,116, IBEX 35 -1.22% at 17,593, PSI -1.00% at 9,033, SMI +0.05% at 13,220, AEX -1.09% at 1,010

UAE categorically rejects Iran's allegations and attempts to justify Iranian attacks that targeted UAE during BRICS meeting

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This development might have implications for sectors reliant on FDA approvals, particularly pharma and biotech, impacting investor sentiment and stock performance in related equities. Traders should monitor how the market reacts, as shifts in leadership can often lead to volatility and shifts in strategic direction.

Related headlines

The whole workspace, free to try.

Try it free